HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential.

Abstract
Protein phosphatase 2A (PP2A) is a tumor suppressor gene, that has been frequently deactivated in many types of cancer. However, its molecular and clinical relevance in oral squamous cell carcinoma (OSCC) remain unclear. Here we show that, PP2A deactivation is a common event in oral cancer cells and hyperphosphorylation in its tyrosine-307 (Y307) residue contributes to PP2A deactivation. PP2A restoration by FTY720 treatment reduced cell growth and decreased GSK-3β phosphorylation without significantly altering other PP2A targets. We further detected PP2A phosphorylation in 262 OSCC tissues. Increased expression of p-PP2A in the tumor tissues was significantly correlated with higher N2/N3-stage (aOR = 2.1, 95%CI: 1.2-3.8). Patients with high p-PP2A expression had lower overall survival rates than those with low expression. Hazard ratio analysis showed that, high p-PP2A expression was significantly associated with mortality density (aOR = 2.2, 95%CI: 1.2-4.0) and lower 10-year overall survival (p = 0.027) in lymph node metastasis. However, no interaction was observed between p-PP2A expression and lymph node metastasis. All our results suggest that PP2A is frequently deactivated in oral cancer and determines poor outcome, restoring its expression by FTY720 can be an alternative therapeutic approach in OSCC.
AuthorsBharath K Velmurugan, Chien-Hung Lee, Shang-Lun Chiang, Chun-Hung Hua, Mei-Chung Chen, Shu-Hui Lin, Kun-Tu Yeh, Ying-Chin Ko
JournalJournal of cellular physiology (J Cell Physiol) Vol. 233 Issue 2 Pg. 1300-1311 (Feb 2018) ISSN: 1097-4652 [Electronic] United States
PMID28516459 (Publication Type: Journal Article)
Copyright© 2017 Wiley Periodicals, Inc.
Chemical References
  • Antineoplastic Agents
  • Enzyme Activators
  • Tyrosine
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Protein Phosphatase 2
  • Fingolimod Hydrochloride
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (pharmacology)
  • Carcinoma, Squamous Cell (drug therapy, enzymology, mortality, pathology)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Enzyme Activators (pharmacology)
  • Female
  • Fingolimod Hydrochloride (pharmacology)
  • Glycogen Synthase Kinase 3 beta (metabolism)
  • Head and Neck Neoplasms (drug therapy, enzymology, mortality, pathology)
  • Humans
  • Kaplan-Meier Estimate
  • Logistic Models
  • Male
  • Middle Aged
  • Mouth Neoplasms (drug therapy, enzymology, mortality, pathology)
  • Multivariate Analysis
  • Neoplasm Staging
  • Odds Ratio
  • Phosphorylation
  • Proportional Hazards Models
  • Protein Phosphatase 2 (metabolism)
  • Risk Factors
  • Signal Transduction (drug effects)
  • Squamous Cell Carcinoma of Head and Neck
  • Time Factors
  • Tyrosine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: